Whether the combination of SFRS2, ASLX1, and IDH2 mutations, in the absence of a JAK2 mutation, is sufficient to confer the MPN phenotype, or describes a unique MPN, is uncertain and warrants further study. Here, IDH2 is linked to myeloproliferative neoplasm.